Zwanger-Pesiri Radiology Implements Konica Minolta Healthcare’s Bone Suppression Imaging Technology to Enhance Chest X-ray Diagnoses

WAYNE, N.J. and CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Zwanger-Pesiri Radiology, one of the most respected and technologically advanced outpatient radiology practices in the Northeast, has implemented Bone Suppression Imaging (BSI) technology from Konica Minolta Healthcare Americas, Inc., to support more precise visualization of pulmonary abnormalities on chest X-rays. Konica Minolta's BSI suppresses the […]

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients

(NASDAQ:INMB), Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation. The results will be presented

Connect Strengthens Leadership Team with Promotion of Cait Kelly to Chief Strategy Officer

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Connect, the premier nonprofit organization in San Diego's innovation ecosystem dedicated to supporting entrepreneurs and cultivating thriving life science and technology communities, announced today that Cait Kelly has been promoted to Chief Strategy Officer and will join the executive leadership team as the organization advances its ongoing

Global Ship Lease Announces Agreement to Acquire Three 8,600 TEU Containerships

(NYSE:GSL), Addition of 3x 2010/2011 Korean-built, 8,600-TEU vessels with ECO upgrades at substantial discount to open-market charter-free values Structured acquisitions with minimal downside risk and attractive upside earnings potential consistent with proven track record of disciplined, opportunistic fleet renewal ATHENS, Greece, Dec. 01, 2025 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”), a

BairesDev Announces Winners of its Inaugural 2025 Developer’s Choice Awards, Identifies the “Essential Enterprise Tech Stack”

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — BairesDev(R), a leading nearshore software development company, today revealed the winners of its inaugural Developer's Choice Awards. The awards spotlight the tools identified by BairesDev's senior development teams as the most impactful on productivity, quality and delivery velocity across global engineering projects. This recognition serves as

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference

BOSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) — Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced participation in one-on-one meetings with investors at the RBC Capital Markets Healthcare Private Company Conference taking place virtually on December 11, 2025. About CerevanceCerevance is focused on advancing

ARKO Corp. Appoints Galagher Jeff as Chief Financial Officer

(NASDAQ:ARKO), RICHMOND, Va., Dec. 01, 2025 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), a Fortune 500 company and one of the largest convenience store operators and fuel wholesalers in the United States, today announced that the Company has appointed Galagher Jeff as its Executive Vice President and Chief Financial Officer, effective

Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference

(NASDAQ:COCP), BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview and clinical progress update at NobleCon 21 – Noble Capital Markets 21st Emerging Growth Equity Conference on Wednesday, December 3, 2025 at 10:00 am Eastern

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

(NASDAQ:SLDB), – SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich's ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the

Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy

(Euronext Amsterdam:NL0000009538),(NYSE:PHG), December 1, 2025 Commercial availability expanded across Europe and the United States Real-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular procedures LumiGuide seamlessly integrates with Azurion, Philips' proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains Amsterdam, the Netherlands and Chicago,

Scroll to Top